BIO-RAD LABORATORIES-A (BIO) Stock Fundamental Analysis
NYSE:BIO - New York Stock Exchange, Inc. - US0905722072 - Common Stock - Currency: USD
Overall BIO gets a fundamental rating of 4 out of 10. We evaluated BIO against 57 industry peers in the Life Sciences Tools & Services industry. While BIO has a great health rating, its profitability is only average at the moment. BIO has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
In the past year BIO was profitable.
In the past year BIO had a positive cash flow from operations.
In multiple years BIO reported negative net income over the last 5 years.
Each year in the past 5 years BIO had a positive operating cash flow.
1.2 Ratios
The Return On Assets of BIO (-19.69%) is comparable to the rest of the industry.
BIO has a Return On Equity of -28.07%. This is comparable to the rest of the industry: BIO outperforms 45.61% of its industry peers.
BIO's Return On Invested Capital of 2.70% is fine compared to the rest of the industry. BIO outperforms 70.18% of its industry peers.
BIO had an Average Return On Invested Capital over the past 3 years of 2.69%. This is significantly below the industry average of 9.60%.
The 3 year average ROIC (2.69%) for BIO is below the current ROIC(2.70%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -19.69% | ||
| ROE | -28.07% | ||
| ROIC | 2.7% |
ROA(3y)-17.25%
ROA(5y)0.31%
ROE(3y)-24.36%
ROE(5y)-0.68%
ROIC(3y)2.69%
ROIC(5y)2.68%
1.3 Margins
Looking at the Operating Margin, with a value of 11.85%, BIO is in the better half of the industry, outperforming 71.93% of the companies in the same industry.
In the last couple of years the Operating Margin of BIO has remained more or less at the same level.
With a decent Gross Margin value of 53.77%, BIO is doing good in the industry, outperforming 66.67% of the companies in the same industry.
In the last couple of years the Gross Margin of BIO has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 11.85% | ||
| PM (TTM) | N/A | ||
| GM | 53.77% |
OM growth 3Y-15.57%
OM growth 5Y1.1%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.9%
GM growth 5Y-0.31%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), BIO is destroying value.
Compared to 1 year ago, BIO has less shares outstanding
BIO has less shares outstanding than it did 5 years ago.
Compared to 1 year ago, BIO has a worse debt to assets ratio.
2.2 Solvency
BIO has an Altman-Z score of 3.50. This indicates that BIO is financially healthy and has little risk of bankruptcy at the moment.
BIO has a Altman-Z score of 3.50. This is in the better half of the industry: BIO outperforms 70.18% of its industry peers.
The Debt to FCF ratio of BIO is 4.51, which is a neutral value as it means it would take BIO, 4.51 years of fcf income to pay off all of its debts.
Looking at the Debt to FCF ratio, with a value of 4.51, BIO is in the better half of the industry, outperforming 71.93% of the companies in the same industry.
A Debt/Equity ratio of 0.18 indicates that BIO is not too dependend on debt financing.
BIO has a Debt to Equity ratio of 0.18. This is in the better half of the industry: BIO outperforms 61.40% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.18 | ||
| Debt/FCF | 4.51 | ||
| Altman-Z | 3.5 |
ROIC/WACC0.25
WACC10.94%
2.3 Liquidity
A Current Ratio of 6.48 indicates that BIO has no problem at all paying its short term obligations.
BIO's Current ratio of 6.48 is amongst the best of the industry. BIO outperforms 80.70% of its industry peers.
BIO has a Quick Ratio of 4.85. This indicates that BIO is financially healthy and has no problem in meeting its short term obligations.
BIO has a Quick ratio of 4.85. This is in the better half of the industry: BIO outperforms 78.95% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.48 | ||
| Quick Ratio | 4.85 |
3. Growth
3.1 Past
BIO shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -12.40%.
BIO shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 7.84% yearly.
The Revenue has decreased by -3.92% in the past year.
The Revenue has been growing slightly by 2.11% on average over the past years.
EPS 1Y (TTM)-12.4%
EPS 3Y-13.02%
EPS 5Y7.84%
EPS Q2Q%-6.45%
Revenue 1Y (TTM)-3.92%
Revenue growth 3Y-4.24%
Revenue growth 5Y2.11%
Sales Q2Q%-2.01%
3.2 Future
The Earnings Per Share is expected to grow by 7.00% on average over the next years.
BIO is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 3.94% yearly.
EPS Next Y-4.93%
EPS Next 2Y5.37%
EPS Next 3Y5.75%
EPS Next 5Y7%
Revenue Next Year0.27%
Revenue Next 2Y2.5%
Revenue Next 3Y3.15%
Revenue Next 5Y3.94%
3.3 Evolution
The EPS growth rate is stable: in the next years the growth will be about the same than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 27.17 indicates a quite expensive valuation of BIO.
Based on the Price/Earnings ratio, BIO is valued a bit cheaper than the industry average as 78.95% of the companies are valued more expensively.
BIO's Price/Earnings ratio indicates a similar valuation than the S&P500 average which is at 29.63.
Based on the Price/Forward Earnings ratio of 28.57, the valuation of BIO can be described as expensive.
Based on the Price/Forward Earnings ratio, BIO is valued a bit cheaper than the industry average as 71.93% of the companies are valued more expensively.
BIO's Price/Forward Earnings ratio indicates a valuation a bit more expensive than the S&P500 average which is at 22.68.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 27.17 | ||
| Fwd PE | 28.57 |
4.2 Price Multiples
Based on the Price/Free Cash Flow ratio, BIO is valued a bit cheaper than 77.19% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 29.46 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)3.47
EPS Next 2Y5.37%
EPS Next 3Y5.75%
5. Dividend
5.1 Amount
No dividends for BIO!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
280.08
-5.55 (-1.94%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners84.5%
Inst Owner Change-89.62%
Ins Owners3.65%
Ins Owner Change0%
Market Cap7.84B
Analysts78.18
Price Target380.29 (35.78%)
Short Float %3.02%
Short Ratio3.05
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)36.08%
Min EPS beat(2)0.1%
Max EPS beat(2)72.05%
EPS beat(4)4
Avg EPS beat(4)32.67%
Min EPS beat(4)0.1%
Max EPS beat(4)72.05%
EPS beat(8)6
Avg EPS beat(8)15.85%
EPS beat(12)8
Avg EPS beat(12)14.81%
EPS beat(16)12
Avg EPS beat(16)21.47%
Revenue beat(2)1
Avg Revenue beat(2)-0.15%
Min Revenue beat(2)-2.71%
Max Revenue beat(2)2.41%
Revenue beat(4)1
Avg Revenue beat(4)-1.18%
Min Revenue beat(4)-2.71%
Max Revenue beat(4)2.41%
Revenue beat(8)1
Avg Revenue beat(8)-2.72%
Revenue beat(12)3
Avg Revenue beat(12)-1.86%
Revenue beat(16)6
Avg Revenue beat(16)0.6%
PT rev (1m)-6.64%
PT rev (3m)-6.17%
EPS NQ rev (1m)-0.99%
EPS NQ rev (3m)1.18%
EPS NY rev (1m)-15.71%
EPS NY rev (3m)-16.7%
Revenue NQ rev (1m)-1.88%
Revenue NQ rev (3m)-5.36%
Revenue NY rev (1m)-2.61%
Revenue NY rev (3m)-3.3%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 27.17 | ||
| Fwd PE | 28.57 | ||
| P/S | 3.06 | ||
| P/FCF | 29.46 | ||
| P/OCF | 17.23 | ||
| P/B | 1.19 | ||
| P/tB | 1.34 | ||
| EV/EBITDA | N/A |
EPS(TTM)10.31
EY3.68%
EPS(NY)9.8
Fwd EY3.5%
FCF(TTM)9.51
FCFY3.39%
OCF(TTM)16.26
OCFY5.8%
SpS91.66
BVpS234.62
TBVpS209.47
PEG (NY)N/A
PEG (5Y)3.47
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -19.69% | ||
| ROE | -28.07% | ||
| ROCE | 3.42% | ||
| ROIC | 2.7% | ||
| ROICexc | 3.32% | ||
| ROICexgc | 3.68% | ||
| OM | 11.85% | ||
| PM (TTM) | N/A | ||
| GM | 53.77% | ||
| FCFM | 10.37% |
ROA(3y)-17.25%
ROA(5y)0.31%
ROE(3y)-24.36%
ROE(5y)-0.68%
ROIC(3y)2.69%
ROIC(5y)2.68%
ROICexc(3y)3.18%
ROICexc(5y)3.05%
ROICexgc(3y)3.46%
ROICexgc(5y)3.26%
ROCE(3y)3.41%
ROCE(5y)3.39%
ROICexcg growth 3Y8.21%
ROICexcg growth 5Y0.05%
ROICexc growth 3Y5.9%
ROICexc growth 5Y-0.58%
OM growth 3Y-15.57%
OM growth 5Y1.1%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.9%
GM growth 5Y-0.31%
F-Score6
Asset Turnover0.27
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.18 | ||
| Debt/FCF | 4.51 | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | 7.36% | ||
| Interest Coverage | -6.54 | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 6.48 | ||
| Quick Ratio | 4.85 | ||
| Altman-Z | 3.5 |
F-Score6
WACC10.94%
ROIC/WACC0.25
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)5.75%
Cap/Sales(5y)5.22%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-12.4%
EPS 3Y-13.02%
EPS 5Y7.84%
EPS Q2Q%-6.45%
EPS Next Y-4.93%
EPS Next 2Y5.37%
EPS Next 3Y5.75%
EPS Next 5Y7%
Revenue 1Y (TTM)-3.92%
Revenue growth 3Y-4.24%
Revenue growth 5Y2.11%
Sales Q2Q%-2.01%
Revenue Next Year0.27%
Revenue Next 2Y2.5%
Revenue Next 3Y3.15%
Revenue Next 5Y3.94%
EBIT growth 1Y-16.75%
EBIT growth 3Y-19.14%
EBIT growth 5Y3.24%
EBIT Next Year51.6%
EBIT Next 3Y21.87%
EBIT Next 5Y18.16%
FCF growth 1Y21.96%
FCF growth 3Y-20.8%
FCF growth 5Y-5.83%
OCF growth 1Y21.41%
OCF growth 3Y-12.07%
OCF growth 5Y-0.12%